<DOC>
	<DOCNO>NCT00274144</DOCNO>
	<brief_summary>Effects AT1 receptor antagonist telmisartan primary endpoint inflammatory parameter patient coronary artery disease ( CAD ) . Secondary endpoint alteration clinical course blood pressure</brief_summary>
	<brief_title>Inflammation Coronary Artery Disease : Role AT1-Receptor Antagonism</brief_title>
	<detailed_description>Methodology : Randomised , double-blind placebo-controlled parallel group design Planned/actual number subject : Enrolled : 40/50 randomise : 40/42 complete : 40/42 Diagnosis main criterion inclusion : Treated essential hypertension mean seat DBP/SBP small 95 mmHg/160 mmHg , coronary artery disease confirm catheterization age equal great 18 year age . Duration treatment : 12 week : telmisartan 40 mg placebo 40 mg Study Hypothesis : The statistical null hypothesis patient CAD mild-to-moderate hypertension , 84-day therapy 40 mg telmisartan cause change inflammatory leukocyte adhesion parameter . The alternative hypothesis therapy influence inflammatory leukocyte adhesion parameter . This hypothesis test nonparametric Wilcoxon test unpaired sample . Comparison ( ) : Placebo 40 mg</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>1 . Treated essential hypertension mean seat DBP &lt; 95 mm Hg mean seat SBP &lt; 160 mm Hg randomisation visit ( baseline ) 2 . Coronary artery disease confirm cardiac catheterization 3 . &gt; 18 year age 4 . Ability stop current antihypertensive therapy ACE inhibitor , angiotensin II receptor antagonist lipid lower therapy statin without risk patient runin period two four week study period . 5 . Ability provide write informed consent . 1 . Acute coronary syndrome . 2 . Acute chronic heart failure ( left ventricular ejection fraction &lt; 45 % ) . 3 . Symptomatic valvular heart disease . 4 . Inflammatory disease ( e.g. , acute infection , rheumatic disease , collagenosis ) . 5 . Premenopausal woman ( last menstruation &lt; 1 year prior start runin period ) : Are surgically sterile . Are nurse . Are childbearing potential NOT practice acceptable mean birth control , NOT plan continue use method throughout study NOT agree submit periodic pregnancy test participation study &gt; 3months duration . Acceptable method birth control include oral , implantable injectable contraceptive . 6 . Known suspected secondary hypertension . 7 . Mean sit SBP &gt; 160 mm Hg mean sit DBP &gt; 95 mm Hg visit . 8 . Hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( ALT ) SGOT ( AST ) &gt; 2 time upper limit normal range . Serum creatinine &gt; 2.3 mg/dL . 9 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , patient postrenal transplant one kidney . 10 . Clinically relevant hypokalaemia hyperkalaemia . 11 . Uncorrected volume depletion . 12 . Uncorrected sodium depletion . 13 . Primary aldosteronism . 14 . Hereditary fructose intolerance . 15 . Biliary obstructive disorder . 16 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonist . 17 . History drug alcohol dependency within 6 month . 18 . Chronic administration medication know affect blood pressure , except medication allow protocol ( cf . 4.2.1 ) . 19 . Current participation another trial , participation trial within period one month . 20 . Known hypersensitivity component formulation . 21 . Has contraindication placebo runin period ( e.g. , recent stroke MI ) . 22 . Any clinical condition , opinion principal investigator , would allow safe completion protocol safe administration telmisartan .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>